Effect of therapy on survival of patients with pancreatic carcinoma
To identify the impact of treatment factors on overall survival in patients with pancreatic carcinoma. We performed a follow-up study on 38 patients with adenocarcinoma of the pancreas treated from 1984 to 1998. 18/38 patients were resected. Irradiated volume included the primary tumor (or tumor bed...
Gespeichert in:
| Veröffentlicht in: | Strahlentherapie und Onkologie 1999-07, Vol.175 (7), p.315-319 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 319 |
|---|---|
| container_issue | 7 |
| container_start_page | 315 |
| container_title | Strahlentherapie und Onkologie |
| container_volume | 175 |
| creator | Warszawski, N Link, K H Warszawski, A Lutz, M P Gansauge, F Schneider, B M Röttinger, E M |
| description | To identify the impact of treatment factors on overall survival in patients with pancreatic carcinoma.
We performed a follow-up study on 38 patients with adenocarcinoma of the pancreas treated from 1984 to 1998. 18/38 patients were resected. Irradiated volume included the primary tumor (or tumor bed) and regional lymph nodes. Thirty-seven patients received in addition chemotherapy consisting of mitoxantrone, 5-fluorouracil and cis-platin, either i.v. (14/38) or i.a. (23/38). The influence of treatment related factors on the overall survival was tested. Biologically effective dose was calculated by the linear-quadratic model (alpha/beta = 25 Gy) and by losing 0.85 Gy per day starting accelerated repopulation at day 28.
Treatment factors influencing overall survival were resection (p = 0.02), overall treatment time (p = 0.03) and biologically effective dose (p < 0.002). Total dose and kind of chemotherapy had no significant influence. Treatment volume had a negative correlation (r = -0.5, p = 0.06) with overall survival, without any correlation between tumor size, tumor stage, and treatment volume. In multivariate analysis only biologically effective dose remained significant (p = 0.02).
Among with surgery, biologically effective dose strongly influences overall survival in patients treated for pancreatic carcinoma. Treatment volume should be kept as small as possible and all efforts should be made to avoid treatment splits in radiation therapy. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69940528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69940528</sourcerecordid><originalsourceid>FETCH-LOGICAL-p542-62c6652a80b245284cbc3d76e25b6f91e5b956f8b0a7a0be0d9bc5102e4b93603</originalsourceid><addsrcrecordid>eNo1j8tqwzAURLVoadK0v1C06s4gyZJsLUtIHxDIJntzJV8RFb8qySn5-7o0XQ0zHA7MDVkzXpmi4qpekfuUPhnjWhp5R1acyVIYI9Zku_MeXaajp_mEEaYLHQea5ngOZ-h-5wlywCEn-h3yaWmDi7hMjjqILgxjDw_k1kOX8PGaG3J83R2378X-8PaxfdkXk5Ki0MJprQTUzAqpRC2ddWVbaRTKam84KmuU9rVlUAGzyFpjneJMoLSm1KzckOc_7RTHrxlTbvqQHHYdDDjOqdHGSLaIF_DpCs62x7aZYughXpr_1-UPVVFSMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69940528</pqid></control><display><type>article</type><title>Effect of therapy on survival of patients with pancreatic carcinoma</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Warszawski, N ; Link, K H ; Warszawski, A ; Lutz, M P ; Gansauge, F ; Schneider, B M ; Röttinger, E M</creator><creatorcontrib>Warszawski, N ; Link, K H ; Warszawski, A ; Lutz, M P ; Gansauge, F ; Schneider, B M ; Röttinger, E M</creatorcontrib><description>To identify the impact of treatment factors on overall survival in patients with pancreatic carcinoma.
We performed a follow-up study on 38 patients with adenocarcinoma of the pancreas treated from 1984 to 1998. 18/38 patients were resected. Irradiated volume included the primary tumor (or tumor bed) and regional lymph nodes. Thirty-seven patients received in addition chemotherapy consisting of mitoxantrone, 5-fluorouracil and cis-platin, either i.v. (14/38) or i.a. (23/38). The influence of treatment related factors on the overall survival was tested. Biologically effective dose was calculated by the linear-quadratic model (alpha/beta = 25 Gy) and by losing 0.85 Gy per day starting accelerated repopulation at day 28.
Treatment factors influencing overall survival were resection (p = 0.02), overall treatment time (p = 0.03) and biologically effective dose (p < 0.002). Total dose and kind of chemotherapy had no significant influence. Treatment volume had a negative correlation (r = -0.5, p = 0.06) with overall survival, without any correlation between tumor size, tumor stage, and treatment volume. In multivariate analysis only biologically effective dose remained significant (p = 0.02).
Among with surgery, biologically effective dose strongly influences overall survival in patients treated for pancreatic carcinoma. Treatment volume should be kept as small as possible and all efforts should be made to avoid treatment splits in radiation therapy.</description><identifier>ISSN: 0179-7158</identifier><identifier>PMID: 10432992</identifier><language>ger</language><publisher>Germany</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - radiotherapy ; Adenocarcinoma - surgery ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - radiotherapy ; Pancreatic Neoplasms - surgery ; Radiotherapy Dosage ; Radiotherapy, Adjuvant ; Survival Rate</subject><ispartof>Strahlentherapie und Onkologie, 1999-07, Vol.175 (7), p.315-319</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10432992$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Warszawski, N</creatorcontrib><creatorcontrib>Link, K H</creatorcontrib><creatorcontrib>Warszawski, A</creatorcontrib><creatorcontrib>Lutz, M P</creatorcontrib><creatorcontrib>Gansauge, F</creatorcontrib><creatorcontrib>Schneider, B M</creatorcontrib><creatorcontrib>Röttinger, E M</creatorcontrib><title>Effect of therapy on survival of patients with pancreatic carcinoma</title><title>Strahlentherapie und Onkologie</title><addtitle>Strahlenther Onkol</addtitle><description>To identify the impact of treatment factors on overall survival in patients with pancreatic carcinoma.
We performed a follow-up study on 38 patients with adenocarcinoma of the pancreas treated from 1984 to 1998. 18/38 patients were resected. Irradiated volume included the primary tumor (or tumor bed) and regional lymph nodes. Thirty-seven patients received in addition chemotherapy consisting of mitoxantrone, 5-fluorouracil and cis-platin, either i.v. (14/38) or i.a. (23/38). The influence of treatment related factors on the overall survival was tested. Biologically effective dose was calculated by the linear-quadratic model (alpha/beta = 25 Gy) and by losing 0.85 Gy per day starting accelerated repopulation at day 28.
Treatment factors influencing overall survival were resection (p = 0.02), overall treatment time (p = 0.03) and biologically effective dose (p < 0.002). Total dose and kind of chemotherapy had no significant influence. Treatment volume had a negative correlation (r = -0.5, p = 0.06) with overall survival, without any correlation between tumor size, tumor stage, and treatment volume. In multivariate analysis only biologically effective dose remained significant (p = 0.02).
Among with surgery, biologically effective dose strongly influences overall survival in patients treated for pancreatic carcinoma. Treatment volume should be kept as small as possible and all efforts should be made to avoid treatment splits in radiation therapy.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Adenocarcinoma - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Chemotherapy, Adjuvant</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - radiotherapy</subject><subject>Pancreatic Neoplasms - surgery</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, Adjuvant</subject><subject>Survival Rate</subject><issn>0179-7158</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8tqwzAURLVoadK0v1C06s4gyZJsLUtIHxDIJntzJV8RFb8qySn5-7o0XQ0zHA7MDVkzXpmi4qpekfuUPhnjWhp5R1acyVIYI9Zku_MeXaajp_mEEaYLHQea5ngOZ-h-5wlywCEn-h3yaWmDi7hMjjqILgxjDw_k1kOX8PGaG3J83R2378X-8PaxfdkXk5Ki0MJprQTUzAqpRC2ddWVbaRTKam84KmuU9rVlUAGzyFpjneJMoLSm1KzckOc_7RTHrxlTbvqQHHYdDDjOqdHGSLaIF_DpCs62x7aZYughXpr_1-UPVVFSMg</recordid><startdate>199907</startdate><enddate>199907</enddate><creator>Warszawski, N</creator><creator>Link, K H</creator><creator>Warszawski, A</creator><creator>Lutz, M P</creator><creator>Gansauge, F</creator><creator>Schneider, B M</creator><creator>Röttinger, E M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199907</creationdate><title>Effect of therapy on survival of patients with pancreatic carcinoma</title><author>Warszawski, N ; Link, K H ; Warszawski, A ; Lutz, M P ; Gansauge, F ; Schneider, B M ; Röttinger, E M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p542-62c6652a80b245284cbc3d76e25b6f91e5b956f8b0a7a0be0d9bc5102e4b93603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>1999</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Adenocarcinoma - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Chemotherapy, Adjuvant</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - radiotherapy</topic><topic>Pancreatic Neoplasms - surgery</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, Adjuvant</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Warszawski, N</creatorcontrib><creatorcontrib>Link, K H</creatorcontrib><creatorcontrib>Warszawski, A</creatorcontrib><creatorcontrib>Lutz, M P</creatorcontrib><creatorcontrib>Gansauge, F</creatorcontrib><creatorcontrib>Schneider, B M</creatorcontrib><creatorcontrib>Röttinger, E M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Warszawski, N</au><au>Link, K H</au><au>Warszawski, A</au><au>Lutz, M P</au><au>Gansauge, F</au><au>Schneider, B M</au><au>Röttinger, E M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of therapy on survival of patients with pancreatic carcinoma</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><addtitle>Strahlenther Onkol</addtitle><date>1999-07</date><risdate>1999</risdate><volume>175</volume><issue>7</issue><spage>315</spage><epage>319</epage><pages>315-319</pages><issn>0179-7158</issn><abstract>To identify the impact of treatment factors on overall survival in patients with pancreatic carcinoma.
We performed a follow-up study on 38 patients with adenocarcinoma of the pancreas treated from 1984 to 1998. 18/38 patients were resected. Irradiated volume included the primary tumor (or tumor bed) and regional lymph nodes. Thirty-seven patients received in addition chemotherapy consisting of mitoxantrone, 5-fluorouracil and cis-platin, either i.v. (14/38) or i.a. (23/38). The influence of treatment related factors on the overall survival was tested. Biologically effective dose was calculated by the linear-quadratic model (alpha/beta = 25 Gy) and by losing 0.85 Gy per day starting accelerated repopulation at day 28.
Treatment factors influencing overall survival were resection (p = 0.02), overall treatment time (p = 0.03) and biologically effective dose (p < 0.002). Total dose and kind of chemotherapy had no significant influence. Treatment volume had a negative correlation (r = -0.5, p = 0.06) with overall survival, without any correlation between tumor size, tumor stage, and treatment volume. In multivariate analysis only biologically effective dose remained significant (p = 0.02).
Among with surgery, biologically effective dose strongly influences overall survival in patients treated for pancreatic carcinoma. Treatment volume should be kept as small as possible and all efforts should be made to avoid treatment splits in radiation therapy.</abstract><cop>Germany</cop><pmid>10432992</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-7158 |
| ispartof | Strahlentherapie und Onkologie, 1999-07, Vol.175 (7), p.315-319 |
| issn | 0179-7158 |
| language | ger |
| recordid | cdi_proquest_miscellaneous_69940528 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - radiotherapy Adenocarcinoma - surgery Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy, Adjuvant Combined Modality Therapy Female Follow-Up Studies Humans Male Middle Aged Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - radiotherapy Pancreatic Neoplasms - surgery Radiotherapy Dosage Radiotherapy, Adjuvant Survival Rate |
| title | Effect of therapy on survival of patients with pancreatic carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T19%3A40%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20therapy%20on%20survival%20of%20patients%20with%20pancreatic%20carcinoma&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=Warszawski,%20N&rft.date=1999-07&rft.volume=175&rft.issue=7&rft.spage=315&rft.epage=319&rft.pages=315-319&rft.issn=0179-7158&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E69940528%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69940528&rft_id=info:pmid/10432992&rfr_iscdi=true |